• Advanced Strategies for Firefly Luciferase mRNA Delivery and

  2026-08-04

  Explore how Firefly Luciferase mRNA with 5-moUTP modification enables precise mRNA delivery and immune activation suppression. This article provides advanced insights for optimizing bioluminescent reporter gene assays using EZ Cap™ Firefly Luciferase mRNA (5-moUTP).

• Disrupting c-MYC/G9a Axis via BRD4-RAC1 Co-Targeting in Brea

  2026-08-03

  This study demonstrates that co-inhibition of BRD4 and RAC1 suppresses breast cancer progression by disrupting the c-MYC–G9a–FTH1 signaling axis and reducing HDAC1 levels. The findings highlight a mechanistically distinct epigenetic vulnerability, informing future research on combinatorial epigenetic therapies in heterogeneous breast cancer subtypes.

• WZ4003: Applied NUAK1/2 Inhibitor Workflows in Cancer & Tauo

  2026-08-03

  WZ4003 stands out as a highly selective NUAK1/2 inhibitor, enabling researchers to dissect cell migration, proliferation, and tau phosphorylation with exceptional specificity. From advanced cancer cell invasion assays to innovative models of neurodegeneration, this APExBIO compound empowers robust, reproducible workflows—now validated by breakthroughs in tau-targeted research.

• 5-hme-dCTP: Precision Mapping for Epigenetic DNA Modificatio

  2026-08-02

  5-hme-dCTP empowers plant researchers to unravel 5-hydroxymethylcytosine's dynamic roles in gene regulation during drought. This guide details robust workflows, troubleshooting, and the latest single-base resolution advances enabled by this modified nucleotide triphosphate.

• CDK9 Inhibitor (A3294): Technical Guidance for Lab Researche

  2026-08-01

  The CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor designed for precise inhibition of CDK9 in transcription elongation and HIV-1 propagation assays. It is not suitable for protocols requiring broad-spectrum CDK inhibition or extended storage of working solutions. Researchers should follow established handling and solubility protocols to ensure data reliability.

• Nanoplastics and Cadmium Co-Exposure Drives Intestinal Apopt

  2026-07-31

  This study demonstrates that simultaneous exposure to polystyrene nanoplastics (PS-NPs) and cadmium (Cd) induces apoptosis in intestinal cells through activation of the IP3R/Ca2+/STAT3 signaling pathway. By dissecting the mechanistic basis of co-contaminant toxicity, the research provides critical insight into environmental risk assessment and the utility of calcium chelation strategies in apoptosis models.

• ZK53 and Mitochondrial ClpP: Precision Tools for Translation

  2026-07-31

  This article examines ZK53—a highly selective activator of the human mitochondrial serine protease ClpP—and its transformative role in cancer research. Integrating mechanistic insights, in vivo validation, and strategic protocol guidance, we illustrate how ZK53 enables researchers to dissect mitochondrial dysfunction and capitalize on vulnerabilities in tumor metabolism. Drawing on recent literature and product intelligence, we position ZK53 as an essential asset for translational research, especially in the context of metabolic reprogramming, ferroptosis sensitization, and the evolving landscape of diet-cancer interplay.

• Ceruletide in Pancreatic Function Research: Protocols & Adva

  2026-07-30

  Ceruletide unlocks reproducible models of pancreatic fibrosis and digestive physiology, enabling nuanced investigation of disease mechanisms and therapeutic testing. This article translates recent breakthroughs into actionable workflows, troubleshooting, and experimental insight for digestive disorder research.

• Metoprolol as a Selective Beta1-Adrenoceptor Antagonist: App

  2026-07-30

  Metoprolol’s selectivity and multifaceted bioactivity make it a gold standard for dissecting cardiovascular, inflammatory, and oncological pathways in preclinical research. This guide details optimized protocols, advanced use-cases, and troubleshooting strategies to maximize experimental clarity and translational relevance.

• Necrostatin-1: Precision RIP1 Kinase Inhibitor for Necroptos

  2026-07-29

  Necrostatin-1 provides rigorous, selective inhibition of the RIP1 kinase pathway, delivering reproducible results in necroptosis assays and acute injury models. Its robust performance in both in vitro and in vivo settings makes it indispensable for dissecting cell death mechanisms and advancing translational research on inflammation and tissue injury.

• Temozolomide (SKU B1399): Reliable DNA Damage Induction in G

  2026-07-29

  This article provides a scenario-driven, evidence-based guide for using Temozolomide (SKU B1399) as a small-molecule alkylating agent in DNA repair and chemotherapy resistance studies. By addressing common laboratory challenges—from solubility optimization to data interpretation and vendor selection—researchers gain actionable insights for robust, reproducible results with Temozolomide.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-07-28

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with their stromal cell subpopulations, closely recapitulating the complex cellular heterogeneity and microenvironment of primary tumors. The approach enhances the physiological relevance of preclinical testing, allowing deeper investigation of drug response variability and mechanisms of resistance.

• RNASEH1-AS1 as a Prognostic lncRNA Biomarker in Hepatocellul

  2026-07-28

  This study provides a comprehensive analysis of the long non-coding RNA RNASEH1-AS1 in hepatocellular carcinoma (HCC), demonstrating its elevated expression, prognostic significance, and mechanistic involvement in tumor progression. The findings highlight RNASEH1-AS1’s potential as a diagnostic and therapeutic target in HCC, with implications for RNA-focused biomarker discovery and targeted molecular studies.

• AZ505 SMYD2 Inhibitor: Advanced Insights for Epigenetic Stud

  2026-07-27

  Explore how AZ505, a potent SMYD2 inhibitor, enables precise epigenetic regulation research and uncovers new mechanistic insights for cancer and kidney disease. This article delivers advanced, application-focused guidance and highlights key innovations beyond current literature.

• Dextran Sulfate Sodium Salt: Optimizing DSS Colitis Models

  2026-07-27

  Dextran sulfate sodium salt (MW 35000-45000) from APExBIO sets the standard for creating reproducible mouse models of ulcerative colitis, enabling advanced dissection of epithelial repair and mucosal inflammation. This article translates the latest mechanistic insights into actionable protocols, troubleshooting tips, and emerging applications for DSS-driven IBD research.

449 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page